Advances in cancer therapy have led to the exploitation of the biological differences between cancer and normal cells. A popular approach is to attach a targeting moiety such as an antibody to a toxin or toxic enzyme in order to specifically locate and kill cancer cells only. However, many immunotoxins have fared poorly in their clinical trials, having shown to elicit immunogenic responses and toxicity in the patient. This problem is commonly attributed to the non-human sources of the toxins and enzymes being delivered. Targeting cytotoxic agents from human sources is therefore a prospective solution. Accordingly, this project aims to develop an immunoconjugate using mammalian or 'mammalian-like' enzymes for the treatment of epithelial cancers over-expressing the MUCl tumour antigen.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:500308 |
| Date | January 2008 |
| Creators | Ahmed, Sarah |
| Publisher | Imperial College London |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.013 seconds